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Abstract
Background: Treatment of acute myocardial infarction with stem cell transplantation has achieved beneficial effects in
many clinical trials. The bone marrow microenvironment of ST-elevation myocardial infarction (STEMI) patients has
never been studied even though myocardial infarction is known to cause an imbalance in the acid-base status of these
patients. The aim of this study was to assess if the blood gas levels in the bone marrow of STEMI patients affect the
characteristics of the bone marrow cells (BMCs) and, furthermore, do they influence the change in cardiac function after
autologous BMC transplantation. The arterial, venous and bone marrow blood gas concentrations were also compared.
Methods: Blood gas analysis of the bone marrow aspirate and peripheral blood was performed for 27 STEMI
patients receiving autologous stem cell therapy after percutaneous coronary intervention. Cells from the bone
marrow aspirate were further cultured and the bone marrow mesenchymal stem cell (MSC) proliferation rate was
determined by MTT assay and the MSC osteogenic differentiation capacity by alkaline phosphatase (ALP) activity
assay. All the patients underwent a 2D-echocardiography at baseline and 4 months after STEMI.
Results: As expected, the levels of pO2,p C O 2,b a s ee x c e s sa n dH C O 3 were similar in venous blood and bone marrow.
Surprisingly, bone marrow showed significantly lower pH and Na
+ and elevated K
+ levels compared to arterial and
venous blood. There was a positive correlation between the bone marrow pCO2 and HCO3 levels and MSC osteogenic
differentiation capacity. In contrast, bone marrow pCO2 and HCO3 levels displayed a negative correlation with the
proliferation rate of MSCs. Patients with the HCO3 level below the median value exhibited a more marked change in
LVEF after BMC treatment than patients with HCO3 level above the median (11.13 ± 8.07% vs. 2.67 ± 11.89%, P = 0.014).
Conclusions: Low bone marrow pCO2 and HCO3 levels may represent the optimal environment for BMCs in terms
of their efficacy in autologous stem cell therapy in STEMI patients.
Keywords: Blood gas analysis, Bone marrow stem cells, Cell therapy, Mesenchymal stem cells, Myocardial infarction
Background
Acute myocardial infarction (AMI) is the major cause of
congestive heart failure and subsequent mortality in the
developed countries. Despite the major advances in treat-
ment methods, myocardial infarction usually causes irre-
versible damage to heart muscle. Cell therapy based on
autologous stem cell transplantation and potential myo-
cardial regeneration has been the focus of many clinical
trials for more than a decade. These trials have yielded
contradictory results which have been proposed to be
attributable to the heterogeneity of the study designs [1].
A recent experimental study showed that donor myocar-
dial infarction impaired the therapeutic potential of bone
marrow cells in mice and it was hypothesized that this
might explain why human cell therapy trials have not
matched the success achieved in rodent experiments [2].
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marrow microenvironment of patients with ST-elevation
myocardial infarction (STEMI) can affect the functional-
ity of the cells used in autologous cell therapy. Myocar-
dial infarction has been shown to result in metabolic
acidosis [3] and base excess in the venous blood has
proved to be an independent predictor for intra-intensive
care unit mortality of STEMI patients [4]. Since the
blood gases measured from venous blood have been
shown to correlate with bone marrow measurements [5],
the acid-base status of STEMI patients likely affects also
the microenvironment of bone marrow. After a careful
literature review, we were not able to find any previous
data on bone marrow physiological conditions in adults.
Thus, the aim of the present study was to assess if the
blood gas or electrolyte levels in the bone marrow of
STEMI patients can influence the characteristics of the
bone marrow cells and, subsequently, the success of
autologous stem cell transplantation. We also compared
arterial, venous and bone marrow blood gas and electro-
lyte concentrations in patients with STEMI. This study is
part of a pilot study (FINCELL II), which followed the
original FINCELL (FINnish stem CELL) trial [6].
Methods
We examined a consecutive series of STEMI patients who
were admitted to the University Hospital of Oulu, Finland,
or to the central hospitals of Kajaani, Rovaniemi or Kemi,
Finland, between April 2008 and August 2009. Inclusion
criteria were age 18-79 years, acute STEMI and depressed
left ventricular function (LVEF < 55%) measured by echo-
cardiography 2-5 days after STEMI. Exclusion criteria
were unwillingness or inability to provide informed con-
sent, NYHA class IV, psychological or physiological
unsuitability for participation in the study, inaccessibility
for follow-up due to geographical or other reasons, severe
leukopenia or thrombocytopenia, hepatic or renal dysfunc-
tion or evidence for malignant disease. Patient characteris-
tics are shown in Table 1. Written informed consent was
obtained from patients within 5 days after STEMI. The
study protocol conformed to the Declaration of Helsinki
and was approved by the Ethical Committee of the North-
ern Ostrobothnia Hospital District. The original FINCELL
trial is registered at http://www.clinicaltrials.gov with
registration number NCT00363324.
Study design
The day of acute STEMI was defined as day 0. On days 1-
5, patients were randomly assigned in a double-blinded
fashion, either to the group receiving the small cell dose
(10 ml, mean cell count 5 × 10
7,n=6 )o rt ot h eg r o u p
receiving the high cell dose (160 ml, mean cell count 7 ×
10
8, n = 21). The patients and investigators performing
the cell injection procedures and analysis of data were
unaware of the randomization throughout the study.
Bone marrow aspiration, collection and preparation of
cells were performed in the morning preceding the intra-
coronary injection of BMCs, which was performed 4-14
days post-STEMI.
Cell preparation, administration and culturing
BMCs were collected in the morning of the cell
administration day under local anesthesia and sterile
conditions. 0.5-1 ml sample was aspirated from one-
two iliac crest into a RAPIDLyte
® heparinized syringe
and the blood gas and electrolyte levels were analysed
using an i-STAT
® Point-of-Care System (Abbot
Laboratories, Illinois, USA). 10 ml or 160 ml of bone
marrow was aspirated and placed into tubes containing
heparinized phosphate buffered saline (PBS; Gibco,
Paisley, UK). The bone marrow cells were then trans-
ported to a culture laboratory dedicated to aseptic cell
manipulation for autologous stem cell transplantation.
The mononuclear cell fraction containing stem and
progenitor cells was isolated by Ficoll density gradient
centrifugation, washed twice with PBS and resus-
pended with 50% autologous serum in heparinized sal-
ine or with heparinized saline alone (total volume of
10 ml). The cells were kept at +4°C until use. The
BMC separation procedure took approximately 3 hours
and the cells were administered within 24 hours to the
target coronary artery. One aliquot of the cell sample
was subjected to quality-control procedures, i.e. micro-
bial culture for sterility and flow cytometer analysis for
CD34+ cell counting and determination of cell viability
in the accredited laboratory of the Oulu University
Hospital, which is subjected to both outside and inside
quality control. The validity of the cell preparation sys-
tem was assessed as described previously [6]. One ali-
quot of the BMC fraction was plated into 25 cm
2
tissue culture flask and cultured in 5 ml medium con-
taining alpha MEM (Gibco) buffered with 20 mM
HEPES (Gibco) and containing 10% heat-inactivated
fetal calf serum (FCS; Bioclear, Netherlands), 100 U/ml
penicillin, 0.1 mg/ml streptomycin, 2 mM L-glutamine
(Gibco). Cells were cultured at +37°C in 5% CO2 and
95% air. After one day, the medium was changed and
non-attached cells were washed away. The attached
cells (mesenchymal stem cells, MSCs) were cultured in
af l a s ka n dt h em e d i u mw a s replaced two times per
week until near-confluence. The cells were passed two
times before the analyses. In the cell counting analyses,
the cells were washed with PBS and adherent cells
detached using trypsin-EDTA solution (Gibco).
Flow cytometric analysis of cell surface antigens
Flow cytometric analysis of cell surface antigens was
performed as previously described [7]. The minimum
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posed by International Society for Cellular Therapy [8]
was evaluated from all MSC lines analyzed, and each of
the lines met the criteria. The percentage values of posi-
tive MSC markers were CD90 99.81 ± 0.23%, CD105
99.58 ± 0.37%, CD73 99.66 ± 0.28% and HLA-ABC
97.58 ± 3.06%. The percentage value of negative markers
(CD14, CD34, CD45, CD19 and HLA-DR) was 1.80 ±
0.58%. Thus, the marker analysis showed that the cell
cultures contained almost purely MSCs.
MTT proliferation assay
MSCs were cultured in 96-well plates in six replicates.
500 cells/well were plated and half of the medium was
changed twice a week. Cell proliferation was measured by
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide) assay after 1, 4, 7, and 14 days culture.
The medium was removed and MTT reagent (Sigma-
Aldrich, St. Louis, MO, USA) (0,5 mg/ml in medium)
was added to the cells and incubated for 2 h at +37°C in
5% CO2 and 95% air. After incubation, the MTT solution
Table 1 Patients characteristics
Low dose
(5 × 10
7), n = 6
High dose
(7 × 10
8), n = 21
Age (years) 56 ± 10 60 ± 9
Male sex (%) 100 95
Body mass index 28 ± 5 28 ± 3
Hypertension [n(%)] 2 (33) 5 (24)
Diabetes [n(%)] 0 1 (5)
TnI max (μg/L) 52 ± 47 51 ± 56
Infarct-related vessel [n(%)]
LAD 3 (50) 6 (29)
CX 0 0
RCA 3 (50) 14 (67)
LOM I 0 1 (5)
LVEF at baseline (%) 47.4 ± 9.2 44.4 ± 6.3
LVEF at 4 months’ follow-up (%) 50.5 ± 13.2 52.3 ± 11.6
TIMI flow before PCI [n(%)]
0 2 (33) 4 (19)
1 1 (17) 2 (10)
2 1 (17) 3 (14)
3 1 (17) 9 (43)
TIMI flow after PCI [n(%)]
10 0
2 1 (17) 2 (10)
3 4 (33) 17 (81)
%Stenosis of the infarct-related artery before PCI 95 ± 5 93 ± 7
Time from STEMI to BMC injection (h) 268 ± 162 214 ± 94
Number of injected BMCs
Number of mononuclear cells (× 10
6) 54 ± 22 701 ± 254
Number of CD34+ cells (× 10
6) 0.75 ± 0.46 8.9 ± 5.1
Adenosine infusion [n(%)] 0 9 (43)
Medication at discharge [n(%)]
ASA 6 (100) 20 (95)
Clopidogrel 6 (100) 21 (100)
Beta-blocker 6 (100) 21 (100)
ACE inhibitor/AT II receptor blocker 6 (100) 21 (100)
Statin 6 (100) 18 (86)
Diuretic 2 (33) 9 (43)
Values are means ± SD. LAD, left anterior descending coronary artery; CX, circumflex coronary artery; RCA, right coronary artery; LOM, left obtuse marginal
coronary artery; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; BMC, bone marrow
stem cell, ASA, acetylsalicylic acid.
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(DMSO; Sigma-Aldrich) was added. The absorbance of
the reduced form of MTT was measured at 550 nm and
650 nm (background) in a plate reader (Victor 2, Wallac
Oy, Turku, Finland).
Alkaline phosphatase activity assay
Human MSCs were seeded at 10000 cells/well into 24-
well plates in four replicate wells and were cultured with
the medium described above and another four replicates
in a medium containing also 100 mM dexamethasone
(Sigma, St. Louis, MO, USA), 10 mM b-glycerol (Sigma)
and 0.05 mM ascorbic acid (Sigma). After 3 weeks, cul-
tured cells were assayed in the following way: the assay
buffer containing 0.1% Triton X-100, pH 7.6, was added
to each well, and the plates were frozen. After thawing,
alkaline phosphatase (ALP) activity was determined using
0.1 mM 4-p-nitrophenylphosphate (Sigma-Aldrich) as
the substrate and absorbance was read at 405 nm in a
plate reader (Victor 2, Wallac Oy, Turku, Finland). Each
sample was measured in duplicate. The protein content
of the wells was determined by the BIO-RAD Protein
Assay (Bio-Rad Laboratories, Richmond, California,
USA). The enzyme activities were expressed as units/mg
protein.
Blood sampling, blood gas and biochemical laboratory
analyses
All the patients underwent venous and arterial blood
sampling on the day of cell transplantation. pH, pO2,
pCO2,H C O 3,B E ,N a
+ and K
+ levels were measured in
the central laboratory of Oulu University Hospital.
Measurement of left ventricular ejection fraction
A 2-dimensional echocardiogram was performed 2-5 days
after STEMI and at 4 months after STEMI. The LVEF was
measured by an experienced investigator in the core
laboratory, unaware of the patient’s treatment assignment,
using the technique described previously [9].
Statistical analysis
Variables are expressed as means ± SD, or medians with
interquartile range with skewed data. Paired samples t-test
was used to determine the statistical significance of the
difference in laboratory values between bone marrow and
arterial/venous blood. Correlation analyses between bone
marrow and arterial/venous blood laboratory values were
conducted using paired samples correlation. In other ana-
lyses, Pearson’s correlation or Spearman’s correlation with
skewed data was used. Analysis-of-variance (ANOVA) was
used in the between-group comparisons. The variance
analyses of the LVEF change in HCO3, BE and potassium
subgroups (above/below median) were corrected with the
cell dose group (low/high dose). All P values are two-tailed
and statistical significance was set at P < 0.05. Analyses
were performed with SPSS software, version 14.0.
Results
Blood gas and electrolyte analyses of bone marrow,
venous and arterial blood
The levels of blood gases (pO2,p C O 2), serum bicarbo-
nate (HCO3), base excess (BE), pH and electrolytes
sodium (Na
+) and potassium (K
+) were measured from
venous, arterial and bone marrow blood samples
(Table 2, Figure 1). All laboratory values measured dif-
fered significantly between bone marrow aspirate and
arterial blood. In addition, a significant difference was
detected between bone marrow aspirate and venous
blood in pH, sodium and potassium levels (Table 2).
The levels of pO2,p C O 2,B Ea n dH C O 3 were similar
in venous blood and bone marrow.
Association of bone marrow blood gas and electrolyte
levels with the functional properties of bone marrow cells
The bone marrow mesenchymal stem cell (MSC) prolif-
eration rate was determined by MTT assay (absorbance/
time in days) (Figure 2A). The absorbance reading was
plotted against time and the slope of the line was used as
the measure of cell proliferation (average slope of all









P value for paired difference (BM vs.
vein)
P value for paired difference (BM vs.
artery)
pH 7.38 ± 0.036 7.40 ± 0.031 7.42 ± 0.048 0.028 0.002
pO2 (kPa) 5.11 ± 0.68 5.63 ± 2.17 11.15 ± 2.79 0.26 < 0.001
pCO2 (kPa) 5.78 ± 0.81 5.62 ± 0.87 4.93 ± 0.84 0.27 < 0.001
HCO3 (mmol/L) 25.43 ± 2.83 25.25 ± 2.85 22.92 ± 1.86 0.66 < 0.001
BE (mmol/L) -0.042 ±
2.46
0.20 ± 2.27 -1.09 ± 1.57 0.56 0.030
Na






+ (mmol/L) 4.96 ± 0.64 4.06 ± 0.37 n.a. 0.000 -
Values are means ± standard deviation. BE = base excess, BM = bone marrow
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capacity was determined by ALP activity assay (u/mg of
protein in basic/differentiation medium) (Figure 2B). The
associations of bone marrow blood gas and electrolyte
levels with BM cell viability (87.9 ± 8.7%), MSC prolifera-
tion rate and the differentiation capacity of MSCs with
bone marrow blood gas and electrolyte levels are pre-
sented in Table 3. Bone marrow pCO2 and HCO3 levels
Figure 1 The comparison of (A) pH, (B) PO2, (C) PCO2, (D) HCO3, (E) BE, (F) natrium, and (G) potassium levels between bone marrow
(BM), venous and arterial blood. P < 0.05 for difference compared to bone marrow.
Miettinen et al. Journal of Translational Medicine 2012, 10:66
http://www.translational-medicine.com/content/10/1/66
Page 5 of 11exhibited a negative correlation with the proliferation
rate of mesenchymal stem cells. In contrast, there was a
positive correlation between the bone marrow pCO2 and
HCO3 levels and MSC ALP activity. This can be inter-
preted as better osteoblast differentiation capacity of
MSCs when bone marrow pCO2 and HCO3 levels are
high. However, none of the biochemical laboratory values
measured was associated with the viability of cells in the
bone marrow aspirate.
Association of bone marrow blood gas and electrolyte
levels with the functional recovery of the heart after cell
therapy
The association of the functional recovery of the heart
after cell therapy with bone marrow blood gas and
electrolyte levels was evaluated by studying the correla-
tions of the blood gases with the change of LVEF
between baseline and the 4 months’ follow-up. There
was a trend towards a negative correlation between
LVEF change and bone marrow HCO3 level as well as
the BE level and a positive correlation between LVEF
change and potassium level, but these associations did
not reach statistical significance (Table 4).
In a further analysis, the patient population was
divided into two subgroups according to their HCO3,
BE and potassium values, respectively, and the cell dose
group was used as a covariate in the analyses. Patients
with the HCO3 level below the median value exhibited a
more marked change in LVEF after stem cell treatment
than patients with the HCO3 level above the median
Figure 2 Tests for bone marrow-derived mesenchymal stem cell (MSC) proliferation and differentiation. (A) MTT proliferation assay. (B)
Alkaline phosphatase (ALP) activity test of MSCs in normal growth medium and osteogenic differentiation medium.
Table 3 Association of bone marrow blood gas and electrolyte levels with functional properties of bone marrow cells
Laboratory variable CD34+ cell viability MSC proliferation rate MSC osteoblast differentiation
Correlation coefficient P-value Correlation coefficient P-value Correlation coefficient P-value
pH 0.093 0.67 0.23 0.31 -0.41 0.095
pO2 (kPa) 0.009 0.97 0.16 0.48 -0.040 0.88
pCO2 (kPa) 0.002 0.99 -0.50 0.023 0.57 0.013
HCO3 (mmol/L) 0.085 0.69 -0.43 0.052 0.48 0.043
BE (mmol/L) 0.083 0.70 -0.41 0.066 0.34 0.17
Na
+ (mmol/L) 0.10 0.64 0.27 0.24 -0.015 0.95
K
+ (mmol/L) 0.147 0.50 0.012 0.96 0.037 0.88
BM = bone marrow, MSC = mesenchymal stem cell
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No significant differences were found in the LVEF
change between BE or potassium subgroups (data not
shown). In addition, the cell dose did not have a signifi-
cant effect on the LVEF change (p = 0.067).
In an attempt to clarify the individual differences in
the levels of bone marrow blood gases, the associations
of several other parameters (e.g. age, sex, body mass
index, hypertension, hypercholesterolemia, diabetes,
heart failure, severity of CAD, medication at discharge)
with the bone marrow blood gas values were tested. The
bone marrow BE and HCO3 levels were found to be
higher in patients using diuretic drugs at the time of
hospital discharge than in patients with no diuretic
medication (BE 1.10 ± 2.81 vs. -0.87 ± 1.81 mmol/L, P
=0 . 0 4 3a n dH C O 3 26.69 ± 3.46 vs. 24.54 ± 1.89 mmol/
L, P = 0.056, respectively). In addition, the patients
using diuretics experienced a smaller improvement in
the LVEF than patients without diuretic medication
(1.81 ± 12.42 vs. 10.24 ± 7.41%-units, respectively, P =
0.036). No significant associations were found between
any other patient characteristics and the bone marrow
blood gases (P = NS in each analysis, data not shown).
Discussion
The results of the present study demonstrate that there
is a significant difference in blood gas and electrolyte
levels between bone marrow and arterial blood in
patients with STEMI. In addition, a significant difference
was found between bone marrow aspirate and venous
blood in pH, sodium and potassium levels. In contrast,
the levels of pO2,p C O 2,B Ea n dH C O 3 were similar in
venous blood and bone marrow. In a further blood gas
analysis, the proliferation ra t eo fb o n em a r r o w - d e r i v e d
MSCs was associated with the pCO2 and HCO3 levels in
the bone marrow. The MSC proliferation was more effi-
cient when bone marrow pCO2 and HCO3 levels were
low. It was also shown that a low HCO3 level in bone
marrow was associated with better functional recovery
of the heart after myocardial infarction treated with
intracoronary injection of autologous BM cells. Patients
with an HCO3 level below the median value experienced
a more marked improvement of LVEF than patients
with the HCO3 level above the median value. In con-
trast, the osteogenic differentiation potential of the BM-
derived MSCs was shown to be better when bone mar-
row pCO2 and HCO3 levels were high.
One objective of this study was to compare arterial,
venous and bone marrow blood gas and electrolyte con-
centrations in STEMI patients. As far as we are aware,
only one previous study has assessed the levels of blood
gases and electrolytes in bone marrow and venous blood
in humans [5]. Grisham et al. studied children with
acute leukemia or other hematological disorders. In
those patients, a significant correlation was found
between venous and bone marrow samples for pH,
pCO2, HCO3, BE and sodium concentration, but no pre-
dictable relationship was observed for pO2 and potas-
sium concentration. In the present study, pCO2,B Ea n d
HCO3 also correlated between bone marrow and venous
blood as well as bone marrow and arterial blood. How-
ever, pH, sodium and potassium levels differed signifi-
cantly between venous blood and bone marrow. In the
study of Grisham et al. the actual differences between
bone marrow and venous blood were not assessed.
However, they also noticed that the potassium levels dif-
fered significantly between bone marrow and venous
blood. They considered that this could be due to the
traumatic nature of specimen collection and the high
Table 4 Association of bone marrow blood gas and
electrolyte levels with the change of LVEF after cell
therapy
Laboratory variable Change of LVEF (%-points)
Correlation coefficient P-value
pH 0.063 0.77
pO2 (kPa) 0.16 0.45
pCO2 (kPa) -0.31 0.13
HCO3 (mmol/L) -0.37 0.070
BE (mmol/L) -0.36 0.082
Na
+ (mmol/L) -0.26 0.23
K
+ (mmol/L) 0.39 0.059
Figure 3 Interaction between bone marrow (BM) HCO3 level
and the absolute change in left ventricular ejection fraction
(LVEF) shown as box (25-75% percentiles) and whiskers (range)
with median (-).* P < 0.05 for difference between the groups.
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ing hemolysis [5]. A portion of the cells inevitably break
during the bone marrow aspiration but we think that
the cell breakage does not fully explain the difference in
potassium concentration between bone marrow and
venous blood because we found a difference also in the
sodium concentration. Instead, it may be a true finding
being related to the different activity of sodium-potas-
sium pump.
Bicarbonate is alkaline, and it is one of the compo-
nents that maintain acid-base homeostasis in the body.
Most of the CO2 in the body is converted into carbonic
acid (H2CO3), which rapidly forms bicarbonate (HCO3
-).
The pH in the body depends on the pCO2 and the level
of HCO3
-. In this study MSC proliferation was found to
be more efficient when the bone marrow aspirate pCO2
and HCO3 levels were low. The pH in the bone marrow
was not directly associated to the proliferation rate but
this may be due to other compensatory buffering
mechanisms, such as hemoglobin, which is known to
stabilize the pH value. It is also known that active
inflammation creates an acidic environment [10]. In the
present study, the levels of pCO2 and HCO3 displayed a
nonsignificant negative correlation with bone marrow
interleukin (IL)-6 levels (data not shown). Thus, the
levels of pCO2 and HCO3 m a yh a v ed e c l i n e di na n
attempt to buffer the acidosis caused by inflammatory
processes. We have previously shown that inflammation
(mediated by tumour necrosis factor alpha) enhances
the proliferation of MSCs and activates many immuno-
suppressive pathways in vitro [7]. Thus, if inflammation
is more extensive in the bone marrow of the patients
with lower levels of pCO2 and HCO3,i tc a nb ep o s t u -
lated to have an influence on the resident MSCs and
enhance also their in vitro proliferation. On the con-
trary, the osteogenic differentiation potential of the BM
cells was found to be better when bone marrow pCO2
and HCO3 levels were high. This result is in line with
previous studies which have shown that acidic environ-
ment impairs osteoblast function,[11,12] reduces osteo-
blast alkaline phosphatase (ALP) activity [13,14] and
inhibits osteogenic differentiation of MSCs [14,15].
Several previous trials have shown that the number of
bone marrow CD34+ cells does not correlate with the
change of LVEF after cell transplantation [16-19]. In the
present study, the viability of CD34+ cells was not asso-
ciated with the pCO2 and HCO3 levels. In addition, the
observation that low bone marrow pCO2 and HCO3 is
beneficial for BM-derived MSC proliferation but not for
the osteoblast differentiation suggests that maintaining
the stemness of MSCs or some other cell lineage is pre-
dominant in this kind of environment. It has been pre-
viously shown that hMSCsc u l t u r e di nh y p o x i c
conditions (2% oxygen) display significantly improved
expansion characteristics while maintaining their multi-
lineage potential [20]. On the other hand, hypoxia as
such can lead to unfavorable effects in the cultured
cells, such as chromosomal aberrations [21]. Obviously,
one of the most important functions of the bone mar-
row microenvironment is to support the stemness of the
resident BMCs and protect the infinitely dividing cell
population from oxygen derived free radicals that could
theoretically promote the cancer propagation of these
cells. It has also been shown that bone marrow contains
many different microenvironments in which MSCs are
the prominent cell components; these cells play many
important roles including controlling hematopoiesis
[22,23]. Based on our results, it seems that the optimal
environment for BM cells in this respect is associated
with a low bone marrow pCO2 value and reduced
HCO3 levels which support the stemness of BM cells
making them more efficient for cell therapy use and
also more capable of undergoing intrinsic repair
mechanisms. However, the results of this study are still
preliminary findings and the importance of bone mar-
row microenvironment on MSC functionality after two
MSC passages in culture media with 5% CO2 and 95%
air, which are completely different conditions compared
to the bone marrow of STEMI patients, remain to be
elucidated. Further tests in cell cultures are currently
ongoing and will later provide us more insights about
the effect of different environmental factors of the bone
marrow on the functionality of the BM cells.
As far as we are aware, this is the first study to assess
the effects of the metabolic state of bone marrow on the
functional capacity of the bone marrow-derived stem
cells in STEMI patients. It has been previously shown
that age, risk factors for coronary artery disease, diabetes
and heart failure diminish the capacity of the blood-
derived circulating cells to contribute to the functional
repair compared to healthy controls [24-26]. In addition,
when the number and functionality of bone marrow-
derived cells have been analyzed, the presence of heart
failure also has been shown to affect these cells. BMCs
isolated from bone marrow aspirates of patients with
ischemic heart failure have been less effective in achiev-
ing a recovery of blood flow after hind limb ischemia
compared to cells from healthy controls [27]. The com-
parison of the composition and function of BMCs has
demonstrated that the number of granulocyte-macro-
phage colony-forming units (GM-CFUs) is significantly
lower and the migratory capacity of the cells is reduced
in patients with ischemic heart failure as compared to
healthy controls [27,28]. Moreover, chronic heart failure
has been shown to be an independent predictor of bone
marrow cell impairment, whereas the cardiovascular risk
factors have not been statistically predictive [28]. We
have also earlier shown that the energy metabolism of
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50 years old) patients compared to young (< 18 years)
and umbilical cord blood mesenchymal stem cells [29].
In the present study, the age of the patients was not
associated with the parameters describing the metabolic
state of bone marrow or the viability of BMCs. Heart
failure, hypercholesterolemia, diabetes or hypertension
were not associated to these parameters either. How-
ever, this may be due to the small patient number in
each disease group. Further studies with larger patient
populations are needed to clarify the association
between these diseases and the bone marrow metabolic
state. There were also attemp t st oc o l l e c ts a m p l e sf r o m
healthy hip fracture patients and patients undergoing
spinal surgery to compare their bone marrow blood gas
levels with STEMI patients. However, there were serious
technical difficulties in the measurement of the thick
bone marrow sample taken from the open bone and
also arterial blood ‘contamination’. Thus, the
comparison of blood gas values between healthy subjects
and patients with myocardial infarction remains to be
elucidated in future studies.
The LVEF change between baseline and follow-up visit
has been the most widely used endpoint to evaluate the
effectiveness of stem cell transplantation after myocar-
dial infarction [1]. In the present study, patients with
the bone marrow HCO3 level below the median value
experienced a more marked improvement of LVEF after
stem cell treatment than their counterparts with an
HCO3 level above the median value. This clinical trial
was designed to be a dose-response study but no differ-
ence in the LVEF recovery could be observed between
the groups receiving low or high dose of BMCs in this
pilot phase. Thus, it is not likely that the differences in
the cell doses would have affected the EF results of the
present substudy. However, because of the low patient
number, the results of this study have to be interpreted
as descriptive rather than confirmatory when
Figure 4 Association between heart, pulmonary vasculature, peripheral circulation and bone marrow after an ischemic event.
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the bone marrow on the clinical outcome of BMC trea-
ted STEMI patients. More studies with higher patient
number are needed to confirm these preliminary
findings.
The bone marrow BE and HCO3 levels were found to
be significantly higher in patients using diuretic drugs at
the time of hospital discharge than in patients with no
diuretic medication. The patients using diuretics also
experienced less extensive improvement in the LVEF
than the patients with no diuretic medication. The use
of diuretic drugs is usually associated with post-STEMI
hypertension or to venous or pulmonary congestion,
and it is these conditions that most likely are affecting
the blood gas values rather than the medication itself.
Based on the results of the present study, we have cre-
ated a hypothetical model describing the associations
between heart, pulmonary vasculature, peripheral circu-
lation and bone marrow after an ischemic event (Figure
4). In this model, the impaired cardiac function leads to
venous or pulmonary congestion making bone marrow
more acidic and, as a buffering effect, there are eleva-
tions in the pCO2 and HCO3 concentrations in the per-
ipheral circulation as well as in the bone marrow. The
acidic bone marrow microenvironment also impairs the
function of the resident stromal cells which leads to
impaired cardiac regeneration after myocardial infarc-
tion. The course of events creates a vicious cycle causing
even more impairment of cardiac function. This idea is
supported by a previous experimental work which
showed that donor myocardial infarction impaired the
therapeutic potential of bone marrow cells in mice [2].
However, based on the results of the present study, we
cannot be sure if it is the change in cardiac, venous or
pulmonary function that triggers this process. Thus,
further studies with a higher number of patients will be
needed to clarify the pathways which are responsible for
the individual differences in acid-base status and the
metabolic state of the bone marrow in STEMI patients.
We believe that this study suggests that we should not
ignore the role of bone marrow physiology as a regula-
tor of BMC-mediated tissue repair, both therapeutic and
spontaneous.
Conclusions
There is a significant difference in blood gas and elec-
trolyte levels between bone marrow and arterial blood
in patients with STEMI. There are also significant differ-
ences in the pH, sodium and potassium levels between
bone marrow aspirate and venous blood. Even though
bone marrow acid-base status and blood gas levels
resemble more closely venous blood than its arterial
counterpart, the bone marrow seems to form a unique
compartment for maintenance and storage of stromal
cells, similarly to that reported in the context of the
hematopoietic stem cell niche. The proliferation rate of
bone marrow-derived MSCs is more efficient when
bone marrow pCO2 and HCO3 levels are low. In con-
trast, the osteogenic differentiation potential of the BM-
derived MSCs is better when bone marrow pCO2 and
HCO3 levels are high. The STEMI patients with lower
HCO3 levels experience a more marked change in
LVEF. Moreover, patients using diuretic drugs at the
time of hospital discharge tended to have higher bone
marrow pCO2 and HCO3 levels and these patients
experienced a poorer improvement in the LVEF after
stem cell therapy, most probably because of the underly-
ing cardiac or venous congestion affecting also the bone
marrow metabolic state. In this respect, low bone mar-
row pCO2 and HCO3 levels represent the optimal envir-
onment for BM cells in terms of their efficacy in
autologous stem cell therapy in STEMI patients.
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